Other Events ·
Turn Therapeutics updates investor presentation with Phase 2 AD data and Q1 2027 topline expectations
TTRXTurn Therapeutics Inc.
Turn Therapeutics Inc. released an updated corporate investor presentation on November 10, 2026, detailing interim results from its ongoing adaptive Phase 2 trial of GX-03 for moderate-to-severe atopic dermatitis (AD). The data highlights significant treatment separation in key efficacy endpoints, including a 59.3% success rate for Week 4 vIGA-AD with GX-03 versus 30.4% for the vehicle. The company expects topline results from this Phase 2 trial in Q1 2027 and plans to initiate Phase 3 trials for AD and onychomycosis, as well as a Phase 2a trial for hidradenitis suppurativa, throughout 2027. Turn Therapeutics operates in the biotechnology sector, developing precision immunomodulation therapies for inflammatory skin diseases.